General public

Home > General public

What is the NOVELTY study?

The NOVELTY study aims to learn more about diseases that affect the airways in the lungs, including asthma and chronic obstructive pulmonary disease (COPD). The aim is that, in future, the most effective medicines can be given to patients depending on the type of lung disease they have. We are collecting information from ~12,000 people with asthma and/or COPD in 19 countries over at least 3 years.

Most research studies are very strict about whom they include, which means many people with asthma and/or COPD cannot take part; this is where NOVELTY is different. NOVELTY includes a wide range of people so we can get a complete picture of all the different types of asthma and COPD. This includes people who have both asthma and COPD and will help us to understand these diseases better and to help more people.

NOVELTY is an observational study, which means that researchers simply collect health information from patients who are getting their usual treatment. They do not have to take any new or different medicines. We are collecting information about symptoms, treatment, how well the lungs are working and how people are affected by their asthma or COPD day-to-day.

Personalised treatment

NOVELTY could help to develop personalised treatments, which would mean that every person could get the best medicine for them.

Read More

NOVELTY around the world

NOVELTY is the most extensive study of its kind. Click here to find out which countries are involved.

Read More

Baseline characteristics results from the NOVELTY study

A newly-published scientific article reports the differences and similarities among patients diagnosed with asthma and/or COPD in the NOVELTY study.

Read More

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study